Grufity logoGrufity logo

SLGC

2.85USD+0.11(+4.01%)Delayed

SomaLogic, Inc.

Market Summary

USD2.85+0.11Delayed
4.01%

SLGC Alerts

SLGC Stock Price

RSI Chart

Valuation

Market Cap

605.4M

Price/Earnings

-6.6

Price/Sales

7.56

Price/Cashflow

-9.03

Price/Sales

Profitability

Return on Equity

-15.1%

Return on Assets

-13.36%

Fundamentals

Revenue

Revenue (TTM)

101.8M

Revenue Y/Y

108.65%

Revenue Q/Q

194.92%

Earnings

Earnings (TTM)

-83.2M

Earnings Y/Y

20.47%

Earnings Q/Q

-43.32%

Price Action

52 Week Range

13.25
(Low)(High)

Last 7 days

-5.3%

Last 30 days

-10.9%

Last 90 days

-27.1%

Trailing 12 Months

-76.9%

Financial Health

Current Ratio

18.86

Investor Care

Shares Dilution (1Y)

3.51%

Diluted EPS (TTM)

-0.44

Financials for SomaLogic

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue27.1%10280868287
Operating Expenses17.4%251214184155132
  S&GA Expenses25.9%149118967858
  R&D Expenses6.6%6258494340
Net Income9.2%-83.21-91.69-82.04-87.55-73.15
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.3%688686713706719
  Current Assets-5.7%621659690692707
    Cash Equivalents-9.0%380418438439469
  Inventory-10.9%1821141111
  Net PPE25.6%201612106
Liabilities8.5%8679969493
  Current Liabilities22.2%4335282922
  Long Term DebtNaN%-----
    LT Debt, CurrentNaN%-----
    LT Debt, Non CurrentNaN%-----
Shareholder's Equity-0.7%603607617612626
  Retained Earnings-6.3%-558.82-525.88-502.89-498.91-475.61
  Additional Paid-In Capital2.5%1,1621,1341,1211,1111,101
Accumulated Depreciation5.9%1716161515
Shares Outstanding2.2%187183182182181
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-20.0%-80.47-67.05-37.20-36.97-23.03
  Share Based Compensation10.9%4339342826
Cashflow From Investing-108.5%-8.4799-104.18-185.43-210.72
Cashflow From Financing-97.6%5225221497677

Risks

What is the probability of a big loss on SLGC?

79.8%


Probability that SomaLogic stock will be more than 20% underwater in next one year

56.0%


Probability that SomaLogic stock will be more than 30% underwater in next one year.

53.6%


Probability that SomaLogic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SLGC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if SomaLogic was unfortunately bought at previous high price.

Returns

Cumulative Returns on SLGC

Which funds bought or sold SLGC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-148
1,000
-%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-38
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-301,000
512,000
-%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
79,000
79,000
-%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
107,000
107,000
-%
2022-11-15
Tamarack Advisers, LP
REDUCED
-14.29
-712,000
870,000
0.51%
2022-11-15
STATE STREET CORP
ADDED
10.29
-3,317,000
8,030,000
-%
2022-11-15
Balyasny Asset Management LLC
REDUCED
-38.36
-2,628,000
1,719,000
-%
2022-11-15
Tamarack Advisers, LP
UNCHANGED
-
-6,000
9,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%

1–10 of 45

Latest Funds Activity

Are funds buying SLGC calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own SLGC

SomaLogic News

ETF Daily News

SomaLogic (NASDAQ:SLGC) Stock Price Up 4.4%.12 hours ago

SLGC Fair Value

Recent SEC filings of SomaLogic

View All Filings
Date Filed Form Type Document
Nov 18, 2022
424B3
Prospectus Filed
Nov 17, 2022
EFFECT
EFFECT
Nov 17, 2022
424B3
Prospectus Filed
Nov 15, 2022
10-Q
Quarterly Report
Nov 14, 2022
8-K
Current Report
Oct 31, 2022
S-3
S-3
Oct 24, 2022
424B3
Prospectus Filed
Oct 19, 2022
CT ORDER
CT ORDER
Oct 18, 2022
8-K
Current Report
Oct 18, 2022
4
Insider Trading

Latest Insider Trading transactions for SLGC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-13
Gutierrez Ruben
ACQUIRED
-
-
85,510
General Counsel
2022-09-13
Smythe Roy
ACQUIRED
-
-
91,968
Chief Executive Officer
2022-09-13
Graves Amy
ACQUIRED
-
-
60,011
Chief Accounting Officer
2022-09-13
Blakeman Shaun M.
ACQUIRED
-
-
200,294
Chief Financial Officer
2022-04-07
POST RICHARD A
ACQUIRED
190,912
4.7728
40,000
-
2022-03-01
Lillis Charles M.
ACQUIRED
-
-
3,430
-
2022-03-01
Graves Amy
ACQUIRED
-
-
12,500
Chief Accounting Officer
2022-03-01
Smythe Roy
ACQUIRED
-
-
72,500
Chief Executive Officer
2022-03-01
Gutierrez Ruben
ACQUIRED
-
-
10,000
General Counsel
2022-03-01
Harris Melody
ACQUIRED
-
-
48,125
President and COO

1–10 of 21

Roy Smythe
320
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SLGC Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss Unaudited - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue    
Collaboration revenue$ 763$ 763$ 2,288$ 2,288
Other revenue22,3251,65527,0267,306
Total revenue41,71319,99278,83758,632
Operating expenses    
Research and development19,41915,59650,85532,304
Selling, general and administrative51,23620,632118,86348,274
Total operating expenses82,32544,998200,117103,578
Loss from operations(40,612)(25,006)(121,280)(44,946)
Other income (expense)    
Interest income and other, net2,417553,456126
Interest expense0(2)0(1,324)
Change in fair value of warrant liabilities3,371(8,111)30,547(8,111)
Change in fair value of earn-out liability1,260(5,662)26,749(5,662)
Loss on extinguishment of debt, net0(2,693)0(4,323)
Total other income (expense)7,048(16,413)60,752(19,294)
Net loss before income tax benefit(33,564)(41,419)(60,528)(64,240)
Income tax benefit62206220
Net loss(32,942)(41,419)(59,906)(64,240)
Other comprehensive loss    
Net unrealized loss on available-for-sale securities(13)(15)(874)(7)
Foreign currency translation loss(14)(4)(28)(3)
Total other comprehensive loss(27)(19)(902)(10)
Comprehensive loss$ (32,969)$ (41,438)$ (60,808)$ (64,250)
Net loss per share, basic (in usd per share)$ (0.18)$ (0.30)$ (0.33)$ (0.53)
Net loss per share, diluted (in usd per share)$ (0.18)$ (0.30)$ (0.33)$ (0.53)
Weighted-average shares outstanding, basic (in shares)184,407,874137,176,228183,209,213122,268,443
Weighted-average shares outstanding, diluted (in shares)184,407,874137,176,228183,209,213122,268,443
Assay services revenue    
Revenue    
Revenue$ 17,574$ 17,499$ 47,305$ 48,308
Operating expenses    
Cost of revenue11,2648,73729,21522,548
Product revenue    
Revenue    
Revenue1,051752,218730
Operating expenses    
Cost of revenue$ 406$ 33$ 1,184$ 452

SLGC Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets Unaudited - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 380,374$ 439,488
Investments185,963218,218
Accounts receivable, net25,05017,074
Inventory18,49911,213
Deferred costs of services1,217462
Prepaid expenses and other current assets10,1575,097
Total current assets621,260691,552
Non-current inventory3,8104,085
Accounts receivable, net of current portion10,3830
Property and equipment, net of accumulated depreciation of $17,416 and $15,244 as of September 30, 2022 and December 31, 2021, respectively19,9109,557
Other long-term assets5,716908
Intangible assets16,7000
Goodwill10,4650
Total assets688,244706,102
Current liabilities  
Accounts payable20,29515,089
Accrued liabilities16,32411,109
Deferred revenue3,6113,021
Other current liabilities2,44566
Total current liabilities42,67529,285
Warrant liabilities4,63535,181
Earn-out liability13626,885
Deferred revenue, net of current portion32,0152,364
Other long-term liabilities6,113363
Total liabilities85,57494,078
Commitments and contingencies (Note 9)
Stockholders’ equity  
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, $0.0001 par value; 600,000,000 shares authorized; 187,495,940 and 181,552,241 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively1918
Additional paid-in capital1,162,4441,110,991
Accumulated other comprehensive loss(974)(72)
Accumulated deficit(558,819)(498,913)
Total stockholders’ equity602,670612,024
Total liabilities and stockholders’ equity$ 688,244$ 706,102